Last reviewed · How we verify

NCT04440033

Factors Associated with Falling in Parkinson's Disease

Completed NA Last updated 19 September 2024
What this trial tests

NA trial testing Baseline assessment of demographic, anthropometric and clinical characteristics in Parkinson Disease in 10 participants. Completed in 1 December 2023.

Timeline
12 October 2020
Primary endpoint
1 December 2023
1 December 2023

Quick facts

Lead sponsorUniversity Hospital, Ghent
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposescreening
Enrollment10
Start date12 October 2020
Primary completion1 December 2023
Estimated completion1 December 2023
Sites2 locations across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Ghent

Who can join

Adults 18 to 75, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study will be to identify multidisciplinary fall risk factors in persons with stage 3 idiopathic Parkinson's Disease compared to age and sex-matched healthy adults. Both the relative contribution of each independent factor, as well as the interaction between these factors, will be examined. The study will include multidisciplinary assessments, including locomotor, speech, auditory, vestibular and opthalmologic assessments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Other University Hospital, Ghent trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04440033.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing